Pharmaceutical Marketing Strategies: A Framework for Brand Teams

Most brand plans I have seen open with a tactics slide. Programmatic, CTV, email, a speaker program, a new patient app. The tactics are rarely the problem. The problem is that nobody wrote down, in one sentence, who the brand needs to move and why they would move. This guide is a working framework for drug marketing strategies, built for the brand lead or agency strategist who has to turn a forecast and a label into a plan. If you want the broader explainer on what the industry does and who the audiences are, start with the pharmaceutical marketing overview. This page is about choosing.

What a pharmaceutical marketing strategy has to decide

The marketing of pharmaceutical products differs from consumer marketing in one structural way: the person who decides (the prescriber), the person who pays (a payer or PBM), and the person who uses the drug (the patient) are three different parties. A strategy has to say which of them is the bottleneck right now. A brand with great formulary access and low awareness among community oncologists has a very different problem from a brand with strong prescriber intent and a 60 percent prior authorization abandonment rate (hypothetical figures).

So the framework below runs in sequence. Each step narrows the next one.

Step one: define the market you are actually in

"Type 2 diabetes" is not a market. "Adults with type 2 diabetes who have failed metformin, have cardiovascular risk, and are treated by primary care physicians rather than endocrinologists" is closer. The narrower definition tells you who prescribes, which competitor is the current default, and what the switching moment looks like.

Good market definition usually answers four things:

• The treatment decision. New start, switch, add-on, or persistence. Each one has different triggers and different people involved.
• The line of therapy. Where your label and payer coverage put you, not where you wish you were.
• The current default. What a physician does today without you. Often it is a generic, sometimes it is watchful waiting.
• The access reality. Formulary tier, step edits, prior authorization burden. Marketing cannot fix access, but it can be wasted by ignoring it.

Market definition also depends on where the product sits in its life. A launch brand is shaping a market. A mature brand is defending share. A brand two years from loss of exclusivity is managing a decline. The article on pharma marketing across the product lifecycle covers how audiences and budget shift at each stage.

Step two: decide whose behavior has to change

This is where most prescription drug marketing plans get vague. "HCPs and patients" is not an audience strategy. The working question is which specific group, if they behaved differently, would move the forecast the most.

On the professional side, that means prioritizing prescribers by more than historical volume. A high-decile physician who already writes your brand is a retention target. A mid-decile physician who treats the right patients and writes the competitor is often the growth opportunity. The full method for segmentation, targeting, and positioning is in target marketing in pharma, and the practical side of prescriber-level outreach is in pharmaceutical marketing to physicians.

On the patient side, ask whether patients are a real lever. In conditions where patients self-identify, have symptoms they notice, and ask for treatment by name, DTC can drive conversations. In conditions diagnosed by a specialist after a lab test, patient media may do little until diagnosis, and the money is better spent on support programs and adherence. The comparison in HCP vs. DTC marketing walks through when a brand needs both tracks and when one is enough.

Step three: write a position you can defend in MLR

Positioning in pharma is constrained by the label. You can only promote what FDA approved, and claims need substantial evidence. That constraint is useful. It forces a brand to pick the one or two differences that are true, supported, and meaningful to the audience you prioritized in step two.

A workable positioning statement names the audience, the frame of reference (what you are compared against), the point of difference, and the reason to believe. If your reason to believe is a subgroup analysis, talk to medical and regulatory early.

Step four: build a channel mix with a job for each channel

Only now do channels come in. Every channel in the plan should have a written job, a target audience, and a reason it beats the alternatives for that job. If two channels have the same job, one of them is probably redundant.

Search deserves its own planning, because the rules are different from display and the intent signal is strong. See pharmaceutical PPC advertising for policy and tactics. Each format also has its own required elements, which is covered in pharmaceutical ads: formats and required elements.

The channel mix also depends on how your company sells. A brand with a large field force uses media to extend reps. A brand with no reps, or a small key account team, expects media and digital to do the work reps used to do. That difference is laid out in pharma commercial models, and it changes what your media team is accountable for.

Steps five and six: plan compliance and measurement before you spend

Compliance goes in the plan, not on it

FDA regulates prescription drug advertising under 21 CFR Part 202, and OPDP reviews promotional materials and issues untitled and warning letters when it finds problems. Product claim ads need fair balance between benefit and risk information, and broadcast ads need a major statement of risks plus adequate provision for the full prescribing information. Print and many digital formats carry a brief summary or an ISI. These are high-level points, not legal advice, and your regulatory team will have the final word.

The strategic implication is timing. MLR review takes weeks, and it takes longer when a format is new to the reviewers. Data use carries its own review: if you plan to use health data for targeting, privacy and legal need to look at the source, the consent basis, and state laws such as Washington's My Health My Data Act. On the professional side, the PhRMA Code shapes what field teams can offer HCPs, and Open Payments reporting applies to many transfers of value.

Build the MLR calendar into the plan before you commit to dates. The pharmaceutical campaign planning process article puts MLR in the right place in a ten-step timeline.

Decide how you will measure before launch

Measurement is a strategy decision because it determines what you can learn. If you want to know whether NPI-targeted media changed prescribing, you need a holdout or a matched comparison group set up before launch. If you want to know whether DTC drove new patient starts, you need an outcomes measurement partner and enough scale for the result to be readable.

A sensible measurement plan has three layers:

1. Delivery and quality. Did the media run where and to whom it was supposed to? Reach against the target list, viewability, invalid traffic.
2. Engagement. Did the audience interact? Site visits, time on page, HCP portal registrations, sample requests.
3. Business outcome. Did prescribing or patient starts change compared with a group that did not see the media?

Each layer is useful, and each layer is easy to overclaim. The pharma media measurement design guide covers how to set up the outcome layer properly.

What usually goes wrong

• The budget is set before the strategy. Last year's number plus or minus 10 percent, then the team fills it. Better to build a media investment thesis that says what each dollar is supposed to change.
• Everyone is a target. A 40,000 NPI list with no prioritization spreads frequency too thin to matter.
• The position is too clever. It tests well in market research and dies in MLR.
• Channels are added, never removed. Nothing is stopped because nothing was measured well enough to stop.
• Measurement is bolted on. Without a holdout set up before launch, the readout becomes a correlation dressed up as attribution.

Practical takeaway

Before your next planning meeting, write one sentence for each of the six decisions: the market, the priority audience, the position, the job of each channel, the compliance constraint that worries you most, and the outcome you will measure. If any sentence takes more than a minute to write, that is where the strategy work is. Fix that gap before anyone opens a media plan template.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.